86 related articles for article (PubMed ID: 7508792)
1. False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy.
Alcover J; Filella X; Barranco MA; Molina R; Ballesta AM; Carretero P
Arch Ital Urol Androl; 1993 Dec; 65(6):657-60. PubMed ID: 7508792
[TBL] [Abstract][Full Text] [Related]
2. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
[TBL] [Abstract][Full Text] [Related]
3. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
[TBL] [Abstract][Full Text] [Related]
4. [Determination of tumor markers in the diagnosis of prostatic cancer].
Casas Terrón E; Mari Ruiz M; Molina Andreu E
Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585
[TBL] [Abstract][Full Text] [Related]
5. Serum PSA and PAP measurements discriminating patients with prostate carcinoma from patients with nodular hyperplasia.
Shih WJ; Collins J; Mitchell B; Wierzbinski B
J Natl Med Assoc; 1994 Sep; 86(9):667-70. PubMed ID: 7525979
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
7. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
8. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
[TBL] [Abstract][Full Text] [Related]
9. [Effects of prostatic massage on serum levels of prostatic acid phosphatase and specific antigen].
Sahin A; Ozen H; Balbay D; Bircan K; Koray Z; Karaagaoglu E; Remzi D
Bull Cancer; 1992; 79(11):1097-100. PubMed ID: 1284587
[TBL] [Abstract][Full Text] [Related]
10. [Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay].
Akino H; Tsuka H; Okada K; Tsuchiya Y; Matsubara M; Arimura K
Hinyokika Kiyo; 1995 Jun; 41(6):439-45. PubMed ID: 7544063
[TBL] [Abstract][Full Text] [Related]
11. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
[TBL] [Abstract][Full Text] [Related]
12. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of specific antigen and prostatic acid phosphatase specificity. Study of false values.
Morote J; Ruibal A; Palou J
Int J Biol Markers; 1986; 1(3):141-6. PubMed ID: 2448398
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
15. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
Shetty SD; Cerny JC
Henry Ford Hosp Med J; 1992; 40(1-2):93-8. PubMed ID: 1385363
[TBL] [Abstract][Full Text] [Related]
16. Bladder catheterization and a plasma prostate-specific antigen in patients with benign prostatic hyperplasia and complete urine retention.
Dutkiewicz S; Stepień K; Witeska A
Mater Med Pol; 1995; 27(2):71-3. PubMed ID: 8935194
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
18. [The diagnostic utility of PSA density].
Alcover J; Filella J; Vendrell JR; Molina R; Ballesta AM; Carretero P
Actas Urol Esp; 1995 Mar; 19(3):192-5. PubMed ID: 8659275
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
20. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.
Morote Robles J; Ruibal Morell A; Palou Redorta J; de Torres Mateos JA; Soler Roselló A
Eur Urol; 1988; 14(5):360-6. PubMed ID: 2458936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]